Research Study for those with Prodromal to Mild Alzheimer’s Disease

IRB/UVA Tracking #
20773
Principal Investigator
Manning Carol, A
Contact First Name

Colleen

Contact Last Name

Webber

Contact Email
Contact Phone
Official Trial Title
GRADUATE:A PHASE III, MULTICENTER, RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED,
PARALLEL-GROUP, EFFICACY, AND SAFETY
STUDY OF GANTENERUMAB IN PATIENTS WITH
EARLY (PRODROMAL TO MILD) Alzheimer's
DISEASE
Study Description

The Adult Neurology Department seeks adults ages 50-90 with Prodromal to Mild Alzheimer’s Disease for a research study. The purpose of the study is to see if an investigational drug is safe and effective for people with Prodromal to Mild Alzheimer’s disease.

You may be eligible for this study if:
*You have a diagnosis of Mild Cognitive Impairment or Mild Alzheimer’s disease, or memory/thinking issues which may be the signs of the condition
*Have an available study partner who knows you well and agrees to participate
*You are in good general health with stable medications

Study involves injections of an investigational medication or placebo, neuropsychological testing, MRI scans, ECG’s, blood draws, and Amyloid PET scans. The study involves up to 43 doses over 104 weeks and cognitive testing every 6 months. After the first 4 injections at the study site homecare can be arranged for many of the subsequent doses.

*All Study-related procedures provided free of charge.
*Compensation for travel of up to $75.00 for each successfully completed study visit and an additional$50.00 for each MRI scan

Compensation

See below